Hydroxychloroquine/Sorafenib

羟氯喹/索拉非尼

Report date: 2025/05/15 20:00:08

Base Information

Drug NameHydroxychloroquine/Sorafenib
Drug Alias Name索拉非尼+羟氯喹Hydroxychloroquine+SorafenibSorafenib Tosylate/Hydroxychloroquine hydrosulfate索拉非尼/羟氯喹Sorafenib+Hydroxychloroquine +[8] 
ClassificationSmall molecules
Mechanisms of ActionVascular endothelial growth factor receptor 3 antagonistsSerine/threonine-protein kinase B-raf inhibitorsVascular endothelial growth factor receptor 1 antagonists +[9] 
TargetsVascular endothelial growth factor receptor 1Stem cell growth factor receptorVascular endothelial growth factor receptor 3 +[9] 
Therapy Area/IndicationsSolid tumoursOvarian Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsYes Sorafenib TosylateHydroxychloroquine sulfate
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesVg Life Sciences
China Registration ClassN/A

Develop Information

Active CompaniesMedical University Of South Carolina
Inactive CompaniesUT Health San Antonio
Active IndicationsOvarian Neoplasms
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A